FDA clears at-home screening tool to assess risk for lung, liver disease linked to alpha-1

Grifols announced that its at-home service to test for genetic risk related to alpha1-antitrypsin deficiency has received clearance from the FDA.Through a saliva sample, the program (AlphaID At Home) will let individuals know if they are at risk for developing specific lung and/or liver diseases by screening for 14 commonly reported genetic mutations related to alpha1-antitrypsin deficiency (alpha-1), according to a press release from the company. Alpha-1 is the most common risk factor for COPD, according to the release, although it is estimated that 90% of individuals with alpha-1 areRead More

Generated by Feedzy